Human Immunodeficiency Virus (HIV)-1 Therapeutics Market Analysis By Drug Class (Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs), Non-NRTIs, Entry & Fusion, Protease, Integrase Inhibitors, Coreceptor Antagonists), And Segment Forecasts, 2014 - 2025

Published: Oct, 2016 | Pages: 75 | Publisher: Grand View Research
Industry: Pharmaceutical | Report Format: Electronic (PDF)

The global HIV-1 therapeutics market is expected to reach a value of USD 15.8 billion by 2025, growing at a CAGR of 1.4%. According to a new report by Grand View Research, Inc., HIV continues to be one of the most challenging public health issues worldwide.

The key factors responsible for driving the market growth include the increasing incidence of HIV infections especially amongst the youth due to unprotected sexual practices, exposure to needles or syringes contaminated with infected body fluids or tissues, lack of awareness regarding transmission risk factors, etc.The estimated number of people suffering from HIV in 2015 was recorded to be more than 35 million according to AVERT, a UK-based HIV and AIDS charity.

HIV has vastly affected people from developing and under developed countries, mainly the Asian and African regions. As this infection is not curable at present, the primary aim of antiretroviral therapy is to suppress viral replication in patients usinganti-retroviral agents that are grouped into six different drug classes based on their mechanism of action.

The combination therapy entails medicines from at least two to three drug classes as each class targets different steps in the HIV lifecycle. The combination of drugs is chosen based on patients' medical history, predisposition to adverse effects of antiretroviral drugs, co-infections with other diseases, and others.

Further Key Findings from the Study Suggest:

NRTIs were the largest class of drugs available in the market in 2015 accounting for over 40% of total drugs available in this vertical

Integrase inhibitors segment is expected to be the fastest growing class of antiretroviral drugs owing to the expected launch of additional integrase inhibitors by major players such as Gilead Sciences, In. and Merck & Co., Inc.

In 2015, North America held the largest market share in 2015 with a share of over 35%. Easier access to diagnostic facilities is one of the key factors supporting sector expansion in this region.

Asia Pacific is projected to be the fastest growing regional segment and will retain its position over the forecast period owing to the enhancing healthcare infrastructure and presence of suitable government initiatives favoring growth

Gilead Sciences, Inc. was the leader in HIV-1 therapeutics sector with respect to market share and drug portfolio, followed byViiV Healthcare in 2015. In addition, in the coming years other small players are expected to enter this sector with their pipeline drugs.

Other important players in this industry include AbbVie, Inc., Bristol-Myers Squibb Company, Merck & Co., Inc., and Boehringer Ingelheim GmbH.

 Table of Content


Chapter 1 Methodology & Scope
                   1.1 Research Methodology
                   1.2 Research Scope & Assumptions
                   1.3 List of Data Sources
Chapter 2 Executive Summary and Market Snapshot
                   2.1 Market Snapshot
Chapter 3 HIV-1 Therapeutics Market Variables, Trends& Scope
                   3.1 Market segmentation & scope
                   3.2 Market size and growth prospects
                      3.2.1 Market Driver Analysis 
                      3.2.2 Market Restraint Analysis
                   3. Penetration & growth prospect mapping
                   3.4 HIV-1 Therapeutics Market - SWOT Analysis, By Factor (political & legal, economic and technological)
                   3.5 Industry Analysis - Porter's
Chapter 4 HIV-1 TherapeuticsMarket Drug Class Estimates & Trend Analysis
                   4.1 HIV-1 Therapeutics market: Drug Class movement analysis
                   4.2 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)
                      4.2.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs) market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                   4.3 Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)
                      4.3.1 Nucleoside-Analog Reverse Transcriptase Inhibitors (NRTIs)market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                   4.4 Entry and Fusion Inhibitors
                      4.4.1 Entry and fusion Inhibitors market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                   4.5 Protease Inhibitors (PIs)
                      4.5.1 Protease Inhibitors (PIs) market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                   4.6 Integrase Inhibitors
                      4.6.1 Integrase inhibitors market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                   4.7 Coreceptor Antagonists
                      4.7.1 Coreceptor antagonists market estimates and forecasts, by drug class, 2014 - 2025 USD Million
Chapter 5 HIV-1 Therapeutics Market Regional Estimates & Trend Analysis
                   5.1 HIV-1 Therapeutics market share by region, 2014& 2025
                   5.2 North America
                      5.2.1 North America market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                            5.2.1.1 U.S.
                            5.2.1.2 Canada
                   5.3 Europe
                      5.3.1 Europe market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                            5.3.1.1 UK
                            5.3.1.2 Germany
                   5.4 Asia Pacific
                      5.4.1 Asia Pacific market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                            5.4.1.1 Japan
                            5.4.1.2 China
                            5.4.1.3 India
                   5.5 Latin America
                      5.5.1 Latin America market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                            5.5.1.1 Mexico
                            5.5.1.2 Brazil
                   5.6 MEA
                      5.6.1 MEA market estimates and forecasts, by drug class, 2014 - 2025 USD Million
                            5.6.1.1 South Africa
Chapter 6 Competitive Landscape
                   6.1 Strategy framework
                   6.2 Company Profiles
                      6.2.1 AbbVie, Inc.
                            6.2.1.1 Company Overview
                            6.2.1.2 Financial Performance
                            6.2.1.3 Product Benchmarking
                            6.2.1.4 Strategic Initiatives
                      6.2.2 Boehringer Ingelheim GmbH
                            6.2.2.1 Company Overview
                            6.2.2.2 Financial Performance
                            6.2.2.3 Product Benchmarking
                            6.2.2.4 Strategic Initiatives
                      6.2.3 Bristol-Myers Squibb Company
                            6.2.3.1 Company Overview
                            6.2.3.2 Financial Performance
                            6.2.3.3 Product Benchmarking
                            6.2.3.4 Strategic Initiatives
                      6.2.4 Cipla, Inc.
                            6.2.4.1 Company Overview
                            6.2.4.2 Financial Performance
                            6.2.4.3 Product Benchmarking
                            6.2.4.4 Strategic Initiatives
                      6.2.5 Genentech, Inc.
                            6.2.5.1 Company Overview
                            6.2.5.2 Financial Performance
                            6.2.5.3 Product Benchmarking
                            6.2.5.4 Strategic Initiatives
                      6.2.6 Gilead Sciences, Inc.
                            6.2.6.1 Company Overview
                            6.2.6.2 Financial Performance
                            6.2.6.3 Product Benchmarking
                            6.2.6.4 Strategic Initiatives
                      6.2.7 Merck & Co., Inc.
                            6.2.7.1 Company Overview
                            6.2.7.2 Financial Performance
                            6.2.7.3 Product Benchmarking
                            6.2.7.4 Strategic Initiatives
                      6.2.8 ViiV Healthcare
                            6.2.8.1 Company Overview
                            6.2.8.2 Financial Performance
                            6.2.8.3 Product Benchmarking
                            6.2.8.4 Strategic Initiatives

List of Tables


TABLE 1 Country share estimation
TABLE 2 North America HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 3 U.S. HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 4 Canada HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 5 Europe HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 6 UK HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 7 Germany HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 8 Asia Pacific HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 9 Japan HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 10 China HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 11 India HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 12 Latin America HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 13 Mexico HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 14 Brazil HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 15 MEA HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)
TABLE 16 South Africa HIV-1 therapeutics market, by drug class, 2014 - 2025 (USD Million)